{"disease":{"id":"b-cell-non-hodgkin-s-lymphoma","name":"b cell non hodgkin s lymphoma"},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"ruxience","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06573099","title":"A Real-World Study on Extranodal Lymphoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01787409","title":"Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01799889","title":"Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":326,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04594642","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT01865617","title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04970901","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":false},{"nct_id":"NCT07081022","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01000753","title":"Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04803201","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":170,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03417414","title":"Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT05805943","title":"Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","has_results":false},{"nct_id":"NCT04870853","title":"Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05294731","title":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT00719888","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT02391480","title":"A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03017820","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05091541","title":"A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Nanjing IASO Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06238648","title":"Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT03226704","title":"Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01351935","title":"Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05618327","title":"Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06806033","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05436223","title":"Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hrain Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT02564744","title":"Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Debiopharm International SA","has_results":true},{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05685173","title":"A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04746131","title":"Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":90,"lead_sponsor_name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","has_results":false},{"nct_id":"NCT06911710","title":"The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT05190068","title":"HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT01087294","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05092451","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03955783","title":"Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Sanjay Mohan","has_results":false},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06213636","title":"Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT00723099","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT05050630","title":"Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":73,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT01431209","title":"Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT03424603","title":"Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}